Phase 1 Trial of STX-478 Shows Promise for PI3K-Mutated Solid Tumors with Reduced Toxicity
/0 Comments/in Clinical Trial, Non-Metastatic, Phase 1/by MaxIn Vivo: CRISPR/Cas9 Gene Editing Shows Promise in Prostate Cancer Treatment
/0 Comments/in CRISPR, Preclinical Research/by MaxIn Vitro: Targeted Cancer Therapy with 4armPEG-DD: A Precision Approach for Prostate Cancer
/0 Comments/in Delivery, Preclinical Research/by MaxIn vivo: Menadione Sodium Bisulfite (vitamin K3) as a Pro-Oxidant Therapy for Prostate Cancer
/0 Comments/in Preclinical Research/by MaxPost-hoc of ARASENS for metastatic hormone sensitive prostate cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxDarolutamide Plus ADT and Docetaxel Extends Survival in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk in ARASENS Trial
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxARX517 Achieves Key Safety and Efficacy Milestones in Phase 1/2 Trials for Metastatic Castration-Resistant Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus personalized medicine Pluvicto prostate cancer PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- Newsletter 30/2025 July 27, 2025
- New Immunotherapy Strategy Aims to Turn All Solid Tumors Into Immune Targets July 26, 2025
- Scientists Trace Deadly Shift in Prostate Cancer to Two Key Genes July 26, 2025
- Low-Dose Abiraterone Acetate: Phase 1 Trial Looks Very Promising July 25, 2025